PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2125427
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2125427
According to Mordor Intelligence, the United States ultrasound devices market size was valued at USD 3.11 billion in 2025 and estimated to grow from USD 3.27 billion in 2026 to reach USD 4.22 billion by 2031, at a CAGR of 5.21% during the forecast period (2026-2031).

This report is Segmented by Application (Anesthesiology, Cardiology, Gynecology/Obstetrics, and More), Technology (2D Ultrasound Imaging, 3D & 4D Ultrasound Imaging, Doppler Imaging, and More), Portability (Stationary Systems, and More), End User (Hospitals & Clinics, and More), and Region (Northeast, Midwest, South, West). The Market Forecasts are Provided in Terms of Value (USD).
Medicare increased outpatient imaging payments by 2.9% in 2025, encouraging procedure migration from inpatient suites to ambulatory sites. Hospital groups consequently favor compact cart systems that clear corridors quickly and process higher patient volumes. Joint ventures such as Smith+Nephew and JointVue equip orthopedic centers with 3D ultrasound navigation that bypasses ionizing radiation. Purchasing committees now rank scanners on throughput metrics and cost-per-scan figures, giving an edge to vendors that bundle analytics dashboards with service contracts in the United States ultrasound devices market.
Only 81,080 diagnostic medical sonographers serve the entire country, so machine-learning guidance is indispensable. GE HealthCare and NVIDIA co-developed autonomous protocols on the Isaac platform that cut rescans by up to 30% while improving measurement consistency. Fujifilm Sonosite's Voice Assist lets users issue commands without touching the console, preserving sterile fields in operating rooms. Software upgrades rather than new hardware now represent the most expedient path to value, pushing hospitals to sign multi-year subscription agreements that stabilize vendor revenues within the United States ultrasound devices market.
Section 524B of the FD&C Act now requires extensive cybersecurity documentation, including a software bill of materials, for every connected scanner. Artificial intelligence modules must submit algorithm drift data, stretching review cycles well beyond historic norms. Smaller companies face longer time-to-revenue and may cede ground to legacy manufacturers that maintain in-house regulatory teams. The United States ultrasound devices market therefore risks slower innovation diffusion, particularly for high-growth therapeutic applications.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Radiology held 37.18% of the United States ultrasound devices market share in 2025 through high-volume diagnostic protocols. Critical care, advancing at a 6.42% CAGR, benefits from bedside assessments that shorten intensive-care stays. Cardiology usage broadens under bundled payment models that reward integrated echocardiography and hemodynamic monitoring. Musculoskeletal imaging grows as sports clinics adopt real-time guidance for injections. Urology accelerates after new CPT codes validated ultrasound-guided ablation. Vascular screening remains steady as Medicare funds preventive programs, sustaining baseline demand for the United States ultrasound devices market.
The United States ultrasound devices market size for radiology is projected to expand moderately as workflow improvement tools extract more scans per machine, while critical care gains incremental budget share from emergency departments. Handheld devices lead adoption curves, yet multi-probe cart systems remain indispensable for high-resolution abdominal and pelvic exams. Vendors now bundle elastography and artificial intelligence packages to raise average selling prices despite budget constraints, reinforcing platform stickiness in hospital radiology suites.
3D and 4D platforms captured 42.05% share through superior spatial rendering that enhances obstetric and cardiac diagnostics. High-intensity focused ultrasound, at 5.89% CAGR, transitions from experimental oncology to reimbursed prostate and uterine fibroid therapies. Doppler remains essential for vascular flow studies, and 2D persists in low-acuity settings due to cost advantages.
United States ultrasound devices market size for therapeutic HIFU remains small but accelerates as clinical evidence broadens. FDA reclassification of select therapeutic probes to Class II lowers entry barriers, and academic centers race to secure first-mover advantage. Established vendors integrate thermal dose monitoring, while niche start-ups license beam-forming software. This dual-path innovation sustains price diversity and supports multi-segment growth within the United States ultrasound devices industry.